Nifedipine sustained-release tablets (Ⅰ)

1. Nifedipine is a dihydropyridine calcium antagonist that can selectively inhibit the transmembrane transport of calcium ions into myocardial cells and smooth muscle cells, and inhibit the release of calcium ions from intracellular reservoirs without changing the plasma calcium ion concentration. 2. This product can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm. It can also inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. On the other hand, it can relax peripheral resistance vessels, reduce peripheral resistance, reduce systolic and diastolic blood pressure, and reduce cardiac afterload. 3. This product can delay the sinoatrial node function and atrioventricular conduction of isolated hearts. Electrophysiological studies of whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinoatrial node, and slowing down the sinoatrial node rate.

Nifedipine.

This product is a film-coated tablet, which appears yellow after removing the film coating.

Various types of hypertension and angina pectoris.

Oral: 10~20mg (1~2 tablets) at a time, twice a day. Maximum dose: 40mg (4 tablets) at a time, 0.12g (12 tablets) a day.

1. Liver: Occasionally, jaundice and elevated glutamate oxaloacetate aminotransferase and glutamate pyruvate aminotransferase may occur. 2. Circulatory system: Occasionally, chest pain, headache, flushing, dizziness, palpitations, decreased blood pressure, lower limb edema may occur. 3. Allergies: Occasionally, allergic symptoms such as measles and itching may occur. 4. Digestive system: Occasionally, abdominal pain, nausea, loss of appetite, constipation may occur. 5. Oral cavity: Gum hypertrophy may occur. 6. Metabolic abnormalities: Occasionally, symptoms of hyperglycemia may occur.

Contraindicated in case of hypersensitivity to nifedipine.

Precautions for children: Children are prohibited. Precautions for pregnancy and lactation: 1. Do not take during pregnancy. 2. No appropriate and controlled studies have been conducted for pregnant women. Nifedipine can enter breast milk. Because there are no reports on the possible effects on infants, if nifedipine must be taken during lactation, breastfeeding should be stopped first. Precautions for the elderly: No experiments have been conducted and no reliable references are available.

1. Combined with nitrates, it can control angina attacks and has good tolerance. 2. Combined with beta-receptor blockers, most patients have good tolerance and efficacy for this product, but some patients may induce and aggravate hypotension, heart failure and angina. 3. Combined with digitalis, it may increase the blood digoxin concentration, suggesting that the blood concentration of digoxin should be monitored when using it for the first time, adjusting the dose or stopping this product. 4. Combined with drugs with high protein binding rate, such as dicoumarins, phenytoin sodium, quinidine, quinine, warfarin, etc., the free concentrations of these drugs often change. 5. Combined with cimetidine, the peak plasma concentration of this product increases, pay attention to adjust the dose. 6. When grapefruit juice is taken with this product, the Cmax and AUC of this product increase.

Keep in a light-proof and airtight container.

10 mg

24 months.

YANGTZE River Pharmaceutical Group Jiangsu JOINT STOCK Co., Ltd.

• Founded in:

  1994-07-28

• Address:

  No. 2 Tongjiang East Road, Gaogang District, Taizhou City, Jiangsu Province

• Tax NO.:

  91321200703973749K

• Registered Funds:

  202.679 million yuan

• Website:

  Log in to view

• Email:

  Log in to view